Compare GSBD & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GSBD | BBNX |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 997.9M |
| IPO Year | 2013 | 2025 |
| Metric | GSBD | BBNX |
|---|---|---|
| Price | $8.91 | $16.91 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 5 | 15 |
| Target Price | $8.94 | ★ $25.10 |
| AVG Volume (30 Days) | 763.6K | ★ 1.0M |
| Earning Date | 11-05-2026 | 10-27-2026 |
| Dividend Yield | ★ 14.79% | N/A |
| EPS Growth | ★ 87.27 | 78.95 |
| EPS | ★ 0.09 | N/A |
| Revenue | N/A | ★ $100,251,000.00 |
| Revenue This Year | N/A | $25.28 |
| Revenue Next Year | N/A | $47.19 |
| P/E Ratio | $100.28 | ★ N/A |
| Revenue Growth | N/A | ★ 53.94 |
| 52 Week Low | $8.36 | $8.80 |
| 52 Week High | $10.38 | $32.71 |
| Indicator | GSBD | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 48.77 | 41.87 |
| Support Level | $8.79 | $15.92 |
| Resistance Level | $9.03 | $18.20 |
| Average True Range (ATR) | 0.21 | 1.34 |
| MACD | 0.06 | -0.03 |
| Stochastic Oscillator | 74.37 | 8.88 |
Goldman Sachs BDC Inc is a non-diversified, closed-end management investment company that elected to be regulated as a business development company focused on lending to middle-market companies. The investment objective is to generate current income and, to a lesser extent, capital appreciation through direct originations of secured debt, including the first lien, unitranche and second lien debt, and unsecured debt. It invests in U.S. middle-market companies such as banks and the public debt markets. The company focuses on the negotiation and structuring of the loans or securities in which it invests and holding the investments in its portfolio to maturity. It generates majority revenue in the form of interest income and dividend income.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.